Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in pediatric moderately to severely active ulcerative colitis
2023-509248-86-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis, sponsored by Bristol Myers Squibb. Primary endpoints: Clinical remission (primary), Histological remission (primary) and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509248-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509248-86-00.